Ketamine Treatments of Neuropsychiatric Disorders

Speaker: Gerard Sanacora, MD, PhD George D. Gross and Esther S. Gross Professor of Psychiatry Director, Yale Depression Research Program Co-Director, Yale New Haven Hospital Interventional Psychiatry Service Yale University School of Medicine ________ Learning objectives: Discuss the rationale underlying and history of the development of ketamine as an antidepressant agent Better critically evaluate the longer-term data associated with the use of esketamine nasal spray for major depressive disorder More fully understand the complex contextual issues that complicate the study and clinical implementation of ketamine and other rapidly acting antidepressant agents. ________ Psychiatry and Behavioral Sciences Grand Rounds presentations are for educational purposes and intended only for behavioral/mental health professionals and clinical providers. The views, thoughts, and opinions expressed are the speaker’s own and do not imply any endorsement of any particular viewpoints, positions, products, services, or organizations by the Department of Psychiatry and Behavioral Sciences, UC San Francisco, or the Regents of the University of California.